Evidence map›Paper›PMID 41562599›Full record

ArticleMicrobiology spectrum2026

A novel approach to combat

Matea Modric, Rocco Gentile, Raphael Moll, Ifey Alio, Wolfgang R Streit, Karl-Erich Jaeger, Holger Gohlke, Filip Kovacic

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Matea ModricForschungszentrum Jülich GmbH, Institute of Molecular Enzyme Technology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
Rocco GentileInstitute for Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
Raphael MollDepartment of Microbiology and Biotechnology, University of Hamburg, Hamburg, Germany.
Ifey AlioDepartment of Microbiology and Biotechnology, University of Hamburg, Hamburg, Germany.
Wolfgang R StreitDepartment of Microbiology and Biotechnology, University of Hamburg, Hamburg, Germany.ORCID 0000-0001-7617-7396
Karl-Erich JaegerForschungszentrum Jülich GmbH, Institute of Molecular Enzyme Technology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.ORCID 0000-0002-6036-0708
Holger GohlkeInstitute for Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.ORCID 0000-0001-8613-1447
Filip KovacicForschungszentrum Jülich GmbH, Institute of Molecular Enzyme Technology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.ORCID 0000-0002-0313-427X

Funding

German Research Foundation 267205415 A02German Research Foundation 267205415 A03German Research Foundation 270650915 GRK 2158
6 · The paper itself

Abstract

Phospholipase A (PLA) plays critical roles in cellular physiology, making human PLAs established drug targets. On the other hand, the potential of bacterial PLAs as targets for antimicrobial drug development remains underexplored. In this study, we curated a library of 23 approved and investigational pharmaceuticals, some of which inhibit human PLA-like enzymes, through a combination of ligand structure-based searches and textual mining in literature and compound databases. Experimental screening identified that compounds GW4869, darapladib, and rilapladib significantly inhibit

Indexed as

Anti-Bacterial AgentsDrug RepositioningPhospholipase A2 InhibitorsPseudomonas aeruginosaBacterial ProteinsBiofilmsHumansMicrobial Sensitivity TestsMolecular Dynamics SimulationPseudomonas InfectionsAnti-Bacterial AgentsBacterial ProteinsPhospholipase A2 Inhibitorsantibiotic potentiationantivirulence drugsdarapladibGW4869imipeneminhibitionintracellular bacterial phospholipasesmolecular dynamicsphospholipase APseudomonas aeruginosarilapladib

Identifiers

PMID41562599
PMCPMC12955470

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.